全文获取类型
收费全文 | 97篇 |
免费 | 5篇 |
专业分类
化学 | 42篇 |
晶体学 | 1篇 |
力学 | 1篇 |
数学 | 38篇 |
物理学 | 20篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2019年 | 1篇 |
2017年 | 1篇 |
2016年 | 6篇 |
2015年 | 1篇 |
2014年 | 1篇 |
2013年 | 8篇 |
2012年 | 14篇 |
2011年 | 4篇 |
2010年 | 8篇 |
2009年 | 9篇 |
2008年 | 2篇 |
2007年 | 3篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2004年 | 3篇 |
2002年 | 2篇 |
2000年 | 1篇 |
1999年 | 7篇 |
1998年 | 1篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1993年 | 5篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1982年 | 2篇 |
排序方式: 共有102条查询结果,搜索用时 46 毫秒
101.
B Raju M Ramesh RM Borkar R Srinivas R Padiya SK Banerjee 《Rapid communications in mass spectrometry : RCM》2012,26(16):1817-1831
102.
Roshan M. Borkar Abhinav Kanwal Bandu Raju Sai Sharanya Pulimamidi Agneesh Pratim Das Subhash Mohan Agarwal Sanjay K. Banerjee Ragampeta Srinivas 《Journal of mass spectrometry : JMS》2023,58(8):e4964
Phlorizin (PRZ) is a natural product that belongs to a class of dihydrochalcones. The unique pharmacological property of PRZ is to block glucose absorption or reabsorption through specific and competitive inhibitors of the sodium/glucose cotransporters (SGLTs) in the intestine (SGLT1) and kidney (SGLT2). This results in glycosuria by inhibiting renal reabsorption of glucose and can be used as an adjuvant treatment for type 2 diabetes. The pharmacokinetic profile, metabolites of the PRZ, and efficacy of metabolites towards SGLTs are unknown. Therefore, the present study on the characterization of hitherto unknown in vivo metabolites of PRZ and pharmacokinetic profiling using liquid chromatography-electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS) and accurate mass measurements is undertaken. Plasma, urine, and feces samples were collected after oral administration of PRZ to Sprague–Dawley rats to identify in vivo metabolites. Furthermore, in silico efficacy of the identified metabolites was evaluated by docking study. PRZ at an intraperitoneal dose of 400 mg/kg showed maximum concentration in the blood to 439.32 ± 8.84 ng/mL at 1 h, while phloretin showed 14.38 ± 0.33 ng/mL at 6 h. The pharmacokinetic profile of PRZ showed that the maximum concentration lies between 1 and 2 h after dosing. Decreased blood glucose levels and maximum excretion of glucose in the urine were observed when the PRZ and metabolites were observed in plasma. The identification and characterization of PRZ metabolites by LC/ESI/MS/MS further revealed that the phase I metabolites of PRZ are hydroxy (mono-, di-, and tri-) and reduction. Phase II metabolites are O-methylated, O-acetylated, O-sulfated, and glucuronide metabolites of PRZ. Further docking study revealed that the metabolites diglucuronide metabolite of mono-hydroxylated PRZ and mono-glucuronidation of PRZ could be considered novel inhibitors of SGLT1 and SGLT2, respectively, which show better binding affinities than their parent compound PRZ and the known inhibitors. 相似文献